Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/8/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Dan Shochat

Wrong Dr. Dan Shochat?

Consulting Vice President of Deve...

Phone: (212) ***-****  HQ Phone
Email: d***@***.com
Intellect Neurosciences Inc
550 Sylvan Avenue Suite 101
Englewood Cliffs , New Jersey 07632
United States

Company Description: We also developed a small molecule that was outside of the core focus of the company, but it was a very interesting technology that we acquired from New York...   more

Employment History

Board Memberships and Affiliations

  • Co-Founder
    Celscia Therapeutics


  • Ph.D. , biochemistry
    Louisiana State University Medical Center
  • Bachelor of Science , biology
    Hebrew University
  • Master in Science , physiology
    Hebrew University
18 Total References
Web References
About AMD :: Intellect Neurosciences, Inc, 8 June 2014 [cached]
IN-N01-OX2 development is being led by Dan Shochat, Ph.D., Consulting Vice President Development, an internationally recognized leader in the development of antibody products. Dr. Shochat led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co. and in collaboration with Celltech, Dr. Shochat led the development of the first approved antibody-drug conjugate, Mylotarg®. He also invented the technology and single-vial formulation and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. With Dr. Shochat's expert assistance, Intellect has developed a detailed road-map for IN-N01-OX2 development to lead to the first clinical trials being initiated by the end of 2014.
Life Sciences News Headlines - ADC Review / Journal of Antibody-drug Conjugates [cached]
Intellect's program is led by Dan Shochat, Ph.D., Intellect Neurosciences' Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.
Management Team :: Intellect Neurosciences, Inc, 19 Sept 2012 [cached]
Dan Shochat, Ph.D. Vice President
Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).
Management Team | KaloBios, 15 July 2012 [cached]
Dan Shochat, Ph.D.
Vice President and Head of Non-Clinical Development
Dr. Shochat has served as our Vice President and Head of Non-Clinical Development since January 2004. Prior to this, he co-founded Celscia Therapeutics in 2003 and served as Executive Vice President and Chief Technical Officer before merging Celscia with KaloBios in 2004. Dr. Shochat has 28 years of experience in the biopharmaceutical industry and 34 years of involvement in research and development of antibodies and antibody conjugates for imaging and therapy. Dr. Shochat served as Vice President of Pharmaceutical Development at Deltagen, Inc. from 2001 to 2002. In 1995, Dr. Shochat was the first employee of Coulter Pharmaceutical, Inc. as Vice President of Research and Development, and subsequently was promoted to Senior Vice President and Chief Scientific Officer. At Coulter, he led the development and manufacturing of Bexxar, a novel centrally radiolabeled monoclonal antibody. In 1988 he joined American Cyanamid to establish the Biotechnology Development Section and led it until 1995. Prior to this, Dr. Shochat established the Product R&D Group at Immunomedics Inc. and directed it from 1984 to 1988. Dr. Shochat holds a Bachelor of Science in biology and a Master in Science in physiology from the Hebrew University in Jerusalem, Israel, and a Ph.D. in biochemistry from Louisiana State University Medical Center.
Kalobios Kalo: Gr, good; Bios: Gr, life, 28 July 2011 [cached]
Dan Shochat, Ph.D., Vice President, Head of Non-clinical Development
Dr. Shochat has over 22 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. At Immunomedics, he led the team that developed the approved in vivo tumor-imaging reagent CEA-Scan. He joined American Cyanamid in 1989 to establish their biotechnology development capability and led the team that developed the first approved antibody-drug conjugate, Mylotarg. In 1995, Dr. Shochat became the first employee of Coulter Pharmaceutical, where he established a 'virtual development activity' managing the outsourcing of process development, manufacturing and quality systems by recruiting key experts in each area. He designed and established the process, formulation, and facility to commercially radiolabel the anti-B1 antibody at a 55 curie scale.
Other People with the name "Shochat":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.